Non-Alcoholic Steatohepatitis Treatment Market Regional Analysis:
North American Market Insights
The non-alcoholic steatohepatitis treatment market in North America is projected to hold the largest market share of 40% by the end of 2035. In 2022, the prevalence of NAFLD in this region was 47.8%, where the estimated patient population in the U.S. and Canada is 100 million and 9.3 million by 2030, respectively (NLM). This represents an enlarging consumer base for this sector, solidifying the region’s proprietorship. Additionally, the rising expenditure on the treatment of NASH is expected to boost the global presence of North America. This attracting more pharma pioneers to participate in this landscape. On this note, Pfizer consolidated its position in this category by attaining fast-track designation approval from the FDA for its combination therapy of ervogastat and clesacostat in May 2022.
The exponentially growing obese population in the U.S. is propelling demand in the market. As per the 2024 CDC report, the number of adults in this country with obesity surpassed 100 million, and 22 million of them were severely affected by this chronic condition. This indicates the possible widespread occurrence of NASH in the coming years, creating a surge in this field. Furthermore, the nation’s regulatory framework is proactively approving new therapeutics, which is fostering an accepting atmosphere for this merchandise. For instance, in March 2024, the FDA gave clearance to the first and only medication for NASH, Rezdiffra (resmetirom), developed by Madrigal Pharmaceuticals.
APAC Market Insights
Asia Pacific is predicted to register a notable CAGR in the non-alcoholic steatohepatitis treatment market over the analyzed timeframe. The region represents both the key drivers: enormous patient volume and biological innovations. On this note, NLM identified China as encompassing the highest count of NAFLD-afflicted individuals in the world, with a projection of reaching 314.5 million by 2030. Simultaneously, JETRO reported that the domestic biopharmaceutical and regenerative medicine industry in Japan is poised to reach USD 22 billion by 2030 from USD 10 billion in 2020. This testifies to the increasing focus of both international and local medicine developers on Pacific countries, ensuring the region’s fast progression in this field.
2030 Country-wise Projections of NAFLD-afflicted Population
|
Country |
Number of NAFLD patients (in million) |
|
Japan |
22.7 |
|
South Korea |
11.6 |
|
Australia |
7 |
|
Singapore |
1.8 |
Source: NLM
India is emerging as a drug innovation hub for the market with its recent advances in biotechnology and pharmacology. In addition, the country’s governing bodies are proactively spreading awareness about associated diseases to avail early diagnosis, prevention, and intervention. Following this goal, in April 2024, Apollo Hospital inaugurated its Apollo Fatty Liver Clinic at the Liver Diseases and Transplantation Institute in Chennai. The cutting-edge facility is equipped with advanced diagnostic tools and the latest pharmacological solutions, such as FibroScan Expert 630. Such infrastructural developments are garnering new business opportunities for both domestic and foreign pioneers.
